Streetbeat News

Analyst Ratings

MBLY

Mizuho analyst Vijay Rakesh has maintained a Buy rating on Mobileye Global (NASDAQ:MBLY) but has reduced the price target from $42 to $38.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:38 pm

INTC

Mizuho analyst Vijay Rakesh has maintained a Buy rating on Intel Corporation (NASDAQ:INTC) but has reduced the price target from $58 to $55.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:35 pm

ADBE

CRM

DOCU

NVDA

QQQ

The article discusses the recent tech rally, highlighting the performance of the QQQ index and Nvidia (NVDA). It suggests looking at other tech stocks like Salesforce (CRM) and Adobe (ADBE), which have also seen significant gains and are approaching all-time highs. Salesforce received an analyst upgrade and may raise subscription prices in 2024. Adobe's growth is outpacing DocuSign (DOCU), and both CRM and ADBE have potential to test new highs according to their chart setups.

Portfolio Pulse from Thrash Capital

January 26, 2024 | 7:34 pm

HUM

Mizuho analyst Ann Hynes has maintained a Buy rating on Humana Inc. (NYSE:HUM) but has reduced the price target from $550 to $400.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:33 pm

TSN

Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Tyson Foods (NYSE:TSN) and increased the price target from $44 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:29 pm

HUM

Cantor Fitzgerald analyst Sarah James has downgraded Humana (NYSE:HUM) from Overweight to Neutral and reduced the price target from $597 to $391.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:26 pm

WDC

Barclays analyst Tom O'Malley has maintained an Overweight rating on Western Digital (NASDAQ:WDC) and increased the price target from $65 to $70.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:15 pm

CALT

VERA

Vera Therapeutics Inc (NASDAQ:VERA) stock surged nearly 50% after positive 72-week data from a Phase 2b trial of atacicept for IgA nephropathy (IgAN). Analysts responded with rating upgrades and increased price targets. Oppenheimer initiated coverage with an Outperform rating and a $26 target. Raymond James upgraded to Strong Buy and raised their target from $29 to $37. Wedbush maintained a Neutral rating but increased their target from $16 to $21. The stock's volume significantly exceeded the average. Calliditas Therapeutics AB (NASDAQ:CALT), which also develops IgAN treatments, had its drug Tarpeyo approved by the FDA in December.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 7:13 pm

VZ

Barclays analyst Kannan Venkateshwar has maintained an Overweight rating on Verizon Communications (NYSE:VZ) and increased the price target from $42 to $44.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:12 pm

URI

Barclays analyst Adam Seiden has maintained an Underweight rating on United Rentals (NYSE:URI) but increased the price target from $325 to $400.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:10 pm